Skip to main content
Trial Intelligence

Understand every study
before the first patient is enrolled.

Trial Intelligence reads your study, structures its design, and surfaces the operational, data, and execution risks that matter before enrollment begins.

It produces two deliverables: a free Executive Summary from a public ClinicalTrials.gov NCT, and a paid Study Intelligence Report from that same NCT or from your full protocol. Same engine, same rendered provenance, same versioned generation record.

Free from a public ClinicalTrials.gov NCT. Full-protocol analysis available through a 1-hour paid strategy session under NDA.

Executive Summary
NCT02******

Phase III Immunotherapy Plus Chemotherapy Study in Advanced Non-Small-Cell Lung Cancer

Sponsor
Global Oncology Sponsor
Phase
3
Enrollment
616
Executive Assessment
Prism Trial Intelligence Index™v1
Frontline Phase 3 oncology with combination immunotherapy plus chemotherapy
84/ 100
High Complexity
v1 basis
  • Protocol Complexity Index
  • Operational Burden Index
  • Eligibility Strictness Index
Enters in v2 (corpus required)
  • Amendment Risk Index
  • Enrollment Velocity Index
Contributing Sub-Indices
Protocol Complexity Index(PCI)
Available
87/ 100

Combination regimen, mandatory tumor biopsy, multi-arm randomization

Operational Burden Index(OBI)
Available
82/ 100

Visit cadence and procedure load above frontline oncology average

Eligibility Strictness Index(ESI)
Available
71/ 100

Recent diagnosis with no prior systemic therapy narrows screening pool

Executive Bottom Line
Operational burden is driven by combination dosing logistics and tumor tissue requirements during screening. Eligibility narrows the pool to recently diagnosed patients without prior systemic therapy, which constrains enrollment velocity at community sites.
Recommendation previewStudy Intelligence Report

Site network expansion recommended

Analysis of eligibility criteria against the current site network indicates the screening pool narrows sharply at community oncology sites. Adding academic and tertiary community sites is recommended to protect screening volume.

EvidenceFIND-*Recommendations, evidence citations, and clickable provenance are included in the Study Intelligence Report (Tier 2).
Generated
Date
Current generation date
Engine
Current platform version
Assessment
Current assessment model
Corpus Snapshot
Current corpus
Build
Current release

Demonstration generated by PrismCDM using publicly available ClinicalTrials.gov protocol information (NCT02******). This analysis was independently produced by PrismCDM and has not been reviewed or endorsed by the study sponsor.

See the full sample artifact
The First View, Then the Complete Analysis

If we can do this from a ClinicalTrials.gov registry in minutes, imagine what the same platform does with your full protocol.

Start with the free Executive Summary. Go deeper with the Study Intelligence Report.

Tier 1 · Free

Executive Summary

A rapid, structured view a sponsor, CRO leader, or clinical-development executive uses to decide whether the study warrants deeper investigation.

Input: Public ClinicalTrials.gov NCT

  • Study identification and design overview
  • Phase, therapeutic area, enrollment, and countries
  • Complexity band: Low / Moderate / Elevated
  • Top operational risks and top data-management challenges
  • Estimated timeline range
  • Executive bottom line
  • Artifact source, generation date, engine version, assessment version, and platform build
  • Full source-cited risk analysisTier 2
  • CRF and SDTM domain recommendationsTier 2
  • PTII composite and contributing sub-indicesTier 2
  • Finding-level clickable provenanceTier 2
  • Reproducibility ID and independently versioned engine recordTier 2
Tier 2 · Paid

Study Intelligence Report

The complete analysis a clinical-development team can review and defend. Comprehensive, source-backed, and reproducible.

Input: NCT or full protocol

  • Everything in the Executive Summary
  • Full protocol analysis and source-cited risk breakdown
  • Operational burden and site complexity analysis
  • Visit schedule and endpoint analysis
  • CRF and SDTM domain recommendations
  • Statistical, monitoring, and submission-readiness considerations
  • PTII composite and contributing sub-indices
  • Every finding traceable to protocol section, engine version, evidence record, and source hash
  • Independently versioned engine and assessment record
  • Reproducibility ID for controlled re-generation

When you are ready to build, the Protocol Design Workspace (Tier 3) generates eCRFs, SDTM mapping, and the Schedule of Assessments from your protocol synopsis. The full PrismCDM Platform (Tier 4) runs the study to submission.

AI without provenance is difficult to trust. Clinical teams need to understand not only what AI recommends, but how it reached every conclusion.
The PrismCDM thesis
Early Access

Start with one study.

Generate a free Executive Summary from a ClinicalTrials.gov NCT in minutes. When you are ready, we walk through the full Study Intelligence Report on your protocol, every finding tied to its source, and show how the same platform continues through Protocol Design Workspace and the full PrismCDM Platform.